Having shown that Bcl-xL activation and/or Bax depletion dictates the BTZ-resistant phenotype in MCL cells, this section outlines how Bcl-xL and Bax might correlate with the clinical outcome. This evidence concerns the gene CASC3 and mantle cell lymphoma.